Abbvie M21-307

AbbVie / Episodic Migraine: Phase 3 Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine

Purpose

The purpose of this study is to see if the study drug, BOTOX®, is safe and helps prevent episodic migraines in adults that experience 6-14 migraine days per month and less than 15 headache days per month. This study is for research purposes only. This study will help the sponsor, AbbVie, to learn about BOTOX® safety and effectiveness when compared to placebo (a substance that looks like a drug but has no drug in it) in people experiencing episodic migraines.